Sylvain Blanchon

Dr. Sylvain Blanchon

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2016 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
EKElma El Khouri
Elma El Khouri
LTLucie Thomas
Lucie Thomas
LJLudovic Jeanson
Ludovic Jeanson
EBEMILIE BEQUIGNON
EMILIE BEQUIGNON
BVBenoit Vallette
Benoit Vallette
SASerge Amselem
Serge Amselem

12 June 2012 in Journal of Medical Genetics
Verified
Journal Article
Closed access
PDF file
SBSylvain Blanchon
Sylvain Blanchon
MLMarie Legendre
Marie Legendre
BCBruno Copin
Bruno Copin
PDPhilippe Duquesnoy
Philippe Duquesnoy
GMGuy Montantin
Guy Montantin
SASerge Amselem
Serge Amselem
Background: CCDC39 and CCDC40 genes have recently been implicated in primary ciliary dyskinesia (PCD) with inner dynein arm (IDA) defects and axonemal disorganisation; their contribution to the disease is, however, unknown. Aiming to delineate the CCDC39/CCDC40 mutation spectrum and associated phenotypes, this study screened a large cohort of patients with IDA defects, in whom clinical and ciliary phenotypes were accurately described. Methods: All CCDC39 and CCDC40 exons and intronic boundaries were sequenced in 43 patients from 40 unrelated families. The study recorded and compared clinical features (sex, origin, consanguinity, laterality defects, ages at first symptoms and at phenotype evaluation, neonatal respiratory distress, airway infections, nasal polyposis, otitis media, bronchiectasis, infertility), ciliary beat frequency, and quantitative ultrastructural analyses of cilia and sperm flagella. Results: Biallelic CCDC39 or CCDC40 mutations were identified in 30/34 (88.2%) unrelated families with IDA defects associated with axonemal disorganisation (22 and eight families, respectively). Fourteen of the 28 identified mutations are novel. No mutation was found in the six families with isolated IDA defects. Patients with identified mutations shared a similar phenotype, in terms of both clinical features and ciliary structure and function. The sperm flagellar ultrastructure, analysed in 4/7 infertile males, showed evidence of abnormalities similar to the ciliary ones. Conclusions: CCDC39 and CCDC40 mutations represent the major cause of PCD with IDA defects and axonemal disorganisation. Patients carrying CCDC39 or CCDC40 mutations are phenotypically indistinguishable. CCDC39 and CCDC40 analyses in selected patients ensure mutations are found with high probability, even if clinical or ciliary phenotypes cannot prioritise one analysis over the other.

1 January 2012 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
JPJean-Francois PAPON
Jean-Francois PAPON
LBLaurence Bassinet
Laurence Bassinet
GCGwenaëlle Cariou-Patron
Gwenaëlle Cariou-Patron
FZFrancoise Zerah-Lancner
Francoise Zerah-Lancner
AVAnne-Marie Vojtek
Anne-Marie Vojtek
BLBruno Louis
Bruno Louis
Primary ciliary dyskinesia (PCD) is a rare congenital respiratory disorder characterized by abnormal ciliary motility leading to chronic airway infections. Qualitative evaluation of ciliary beat pattern based on digital high-speed videomicroscopy analysis has been proposed in the diagnosis process of PCD. Although this evaluation is easy in typical cases, it becomes difficult when ciliary beating is partially maintained. We postulated that a quantitative analysis of beat pattern would improve PCD diagnosis. We compared quantitative parameters with the qualitative evaluation of ciliary beat pattern in patients in whom the diagnosis of PCD was confirmed or excluded. Nasal nitric oxide measurement, nasal brushings and biopsies were performed prospectively in 34 patients with suspected PCD. In combination with qualitative analysis, 12 quantitative parameters of ciliary beat pattern were determined on high-speed videomicroscopy recordings of beating ciliated edges. The combination of ciliary ultrastructural abnormalities on transmission electron microscopy analysis with low nasal nitric oxide levels was the “gold standard” used to establish the diagnosis of PCD. This “gold standard” excluded PCD in 15 patients (non-PCD patients), confirmed PCD in 10 patients (PCD patients) and was inconclusive in 9 patients. Among the 12 parameters, the distance traveled by the cilium tip weighted by the percentage of beating ciliated edges presented 96% sensitivity and 95% specificity. Qualitative evaluation and quantitative analysis were concordant in non-PCD patients. In 9/10 PCD patients, quantitative analysis was concordant with the “gold standard”, while the qualitative evaluation was discordant with the “gold standard” in 3/10 cases. Among the patients with an inconclusive “gold standard”, the use of quantitative parameters supported PCD diagnosis in 4/9 patients (confirmed by the identification of disease-causing mutations in one patient) and PCD exclusion in 2/9 patients. When the beat pattern is normal or virtually immotile, the qualitative evaluation is adequate to study ciliary beating in patients suspected for PCD. However, when cilia are still beating but with moderate alterations (more than 40% of patients suspected for PCD), quantitative analysis is required to precise the diagnosis and can be proposed to select patients eligible for TEM.

8 May 2012 in Pediatric Pulmonology
Verified
Journal Article
Open access
PDF file
MMMarie Lémery Magnin
Marie Lémery Magnin
PCPierrick Cros
Pierrick Cros
NBNicole Beydon
Nicole Beydon
MMMalika Mahloul
Malika Mahloul
ATAline Tamalet
Aline Tamalet
SBSylvain Blanchon
Sylvain Blanchon
Background and Objectives: Functional and structural lung evaluations are part of the follow‐up of patients with primary ciliary dyskinesia (PCD). We aimed to evaluate transversal and longitudinal relationships between lung function test (LFT) and chest computed tomography (CT) in children with PCD, in stable clinical condition.Materials and Methods: Data from children followed in the French National Center were retrospectively collected. Inclusion criteria were (i) definitive diagnosis of PCD, (ii) age less than 15 years at the beginning of follow‐up, (iii) at least 8 years of follow‐up, (iv) at least two couples of concurrent CT and LFT available in a phase of clinical stability of the lung disease without modification of the treatment regimen in the last 4 weeks. Twenty children (median age at entry 4.6 years, median follow‐up 15.4 years) were included. Concurrent LFT (blood gas and spirometry) and CT (score) results were recorded.Results: LFT indices (PaO2 (n = 210), FVC, FEV1, FEF2575% (n = 195)) significantly decreased with age, and the mean annual decrease (z‐score (% predicted)) was −0.17 (−0.49%), −0.09 (−0.50%), −0.10 (−0.89%), and −0.07 (−1.73%), respectively. First CT (median age 8.7 years) revealed bronchiectasis (70%), mucous plugging (70%), peribronchial thickening (90%), parenchymal abnormalities (65%), and hyperinflation (50%). CT scores (n = 74) significantly increased with age, and was negatively correlated to PaO2, FVC, FEV1, and FEF2575% longitudinal changes.Conclusion: In stable clinical condition, functional, and structural progressive impairments significantly correlated in children with PCD. Further prospective studies, including large populations of patients with various levels of disease severity, are needed to confirm whether lung function follow‐up can be used to adjust CT frequency and help at minimizing the radiation burden in children with a good life expectancy. Pediatr Pulmonol. 2012. 47:816–825.

5 October 2022 in European Respiratory Review
Verified
Journal Article
Open access
PDF file
GMGeorgia Mitropoulou
Georgia Mitropoulou
AKAngela Koutsokera
Angela Koutsokera
CCChantal Csajka
Chantal Csajka
SBSylvain Blanchon
Sylvain Blanchon
ASAlain Sauty
Alain Sauty
BGBenoit Guery
Benoit Guery
Lower respiratory tract infections lead to significant morbidity and mortality. They are increasingly caused by multidrug-resistant pathogens, notably in individuals with cystic fibrosis, hospital-acquired pneumonia and lung transplantation. The use of bacteriophages (phages) to treat bacterial infections is gaining growing attention, with numerous published cases of compassionate treatment over the last few years. Although the use of phages appears safe, the lack of standardisation, the significant heterogeneity of published studies and the paucity of robust efficacy data, alongside regulatory hurdles arising from the existing pharmaceutical legislation, are just some of the challenges phage therapy has to overcome. In this review, we discuss the lessons learned from recent clinical experiences of phage therapy for the treatment of pulmonary infections. We review the key aspects, opportunities and challenges of phage therapy regarding formulations and administration routes, interactions with antibiotics and the immune system, and phage resistance. Building upon the current knowledge base, future pre-clinical studies using emerging technologies and carefully designed clinical trials are expected to enhance our understanding and explore the therapeutic potential of phage therapy.

26 June 2018 in Pediatric Pulmonology
Verified
Journal Article
Closed access
PDF file
AFAgnès Fina
Agnès Fina
JDJean‐Christophe Dubus
Jean‐Christophe Dubus
ATAntoine Tran
Antoine Tran
JDJocelyne Derelle
Jocelyne Derelle
PRPhilippe Reix
Philippe Reix
LGLisa Giovannini‐Chami
Lisa Giovannini‐Chami